Regeneron Pharmaceuticals, Inc. (0R2M.L)
0R2M.L Stock Price Chart
Explore Regeneron Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze 0R2M.L price movements and trends.
0R2M.L Company Profile
Discover essential business fundamentals and corporate details for Regeneron Pharmaceuticals, Inc. (0R2M.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Pharmaceuticals
IPO Date
5 Nov 2014
Employees
15.16K
Website
https://www.regeneron.comCEO
Leonard S. Schleifer
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
0R2M.L Financial Timeline
Browse a chronological timeline of Regeneron Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 2 Feb 2026
Upcoming earnings on 29 Oct 2025
Upcoming earnings on 1 Aug 2025
Revenue estimate is $3.30B.
Dividend declared on 20 May 2025
A dividend of $0.88 per share was announced, adjusted to $0.88. The dividend was paid on 6 Jun 2025.
Earnings released on 29 Apr 2025
EPS came in at $7.27 falling short of the estimated $8.62 by -15.66%, while revenue for the quarter reached $3.03B, missing expectations by -7.62%.
Dividend declared on 20 Feb 2025
A dividend of $0.88 per share was announced, adjusted to $0.88. The dividend was paid on 20 Mar 2025.
Earnings released on 4 Feb 2025
EPS came in at $8.06 falling short of the estimated $11.28 by -28.55%, while revenue for the quarter reached $3.79B, beating expectations by +8.88%.
Earnings released on 31 Oct 2024
EPS came in at $11.54 falling short of the estimated $11.69 by -1.28%, while revenue for the quarter reached $3.72B, beating expectations by +1.25%.
Earnings released on 1 Aug 2024
EPS came in at $12.41 surpassing the estimated $10.62 by +16.85%, while revenue for the quarter reached $3.55B, beating expectations by +4.83%.
Earnings released on 2 May 2024
EPS came in at $6.27 falling short of the estimated $10.17 by -38.35%, while revenue for the quarter reached $3.15B, missing expectations by -2.49%.
Earnings released on 6 Mar 2024
EPS came in at $10.19 falling short of the estimated $10.73 by -5.03%, while revenue for the quarter reached $3.43B, beating expectations by +4.25%.
Earnings released on 14 Dec 2023
EPS came in at $8.89 falling short of the estimated $10.68 by -16.76%, while revenue for the quarter reached $3.36B, beating expectations by +4.04%.
Earnings released on 3 Aug 2023
EPS came in at $8.50 falling short of the estimated $9.85 by -13.71%, while revenue for the quarter reached $3.16B, beating expectations by +4.47%.
Earnings released on 4 May 2023
EPS came in at $7.17 falling short of the estimated $9.52 by -24.68%, while revenue for the quarter reached $3.16B, beating expectations by +5.42%.
Earnings released on 3 Feb 2023
EPS came in at $10.50 surpassing the estimated $10.25 by +2.44%, while revenue for the quarter reached $3.41B, beating expectations by +9.27%.
Earnings released on 2 Nov 2022
EPS came in at $11.66 surpassing the estimated $9.76 by +19.47%, while revenue for the quarter reached $2.94B, beating expectations by +0.71%.
Earnings released on 3 Aug 2022
EPS came in at $7.47 falling short of the estimated $8.62 by -13.34%, while revenue for the quarter reached $2.86B, beating expectations by +2.25%.
Earnings released on 4 May 2022
EPS came in at $8.61 falling short of the estimated $9.72 by -11.42%, while revenue for the quarter reached $2.97B, beating expectations by +10.22%.
Dividend declared on 15 Mar 2022
A dividend of $0.29 per share was announced, adjusted to $0.29.
Earnings released on 4 Feb 2022
EPS came in at $19.69 falling short of the estimated $20.40 by -3.48%, while revenue for the quarter reached $4.95B, beating expectations by +8.53%.
Earnings released on 4 Nov 2021
EPS came in at $27.97, while revenue for the quarter reached $5.14B.
Earnings released on 30 Sept 2021
EPS came in at $14.33, while revenue for the quarter reached $3.45B.
Earnings released on 31 Mar 2021
EPS came in at $10.09, while revenue for the quarter reached $2.53B.
Earnings released on 31 Dec 2020
EPS came in at $10.24, while revenue for the quarter reached $2.42B.
Earnings released on 30 Sept 2020
EPS came in at $7.39, while revenue for the quarter reached $2.29B.
0R2M.L Stock Performance
Access detailed 0R2M.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.